<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291433</url>
  </required_header>
  <id_info>
    <org_study_id>P081239</org_study_id>
    <nct_id>NCT01291433</nct_id>
  </id_info>
  <brief_title>Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy</brief_title>
  <acronym>PENTOCLO</acronym>
  <official_title>Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation-induced brachial plexopathy (RIP) is a rare and severe delayed peripheral nerve&#xD;
      complication of radiotherapy, that is spontaneously irreversible with no medical treatment to&#xD;
      limit or reduce symptoms. The investigators planed in RIP a randomized double blind clinical&#xD;
      trial, using a pentoxifylline (P)- tocopherol (E)- clodronate combination versus placebo, to&#xD;
      assess a possible symptomatic regression by a sensory-motor neurological quantifiable and&#xD;
      reproducible score (modified Subjective Objective Medical management Analytic, SOMA).&#xD;
&#xD;
      The investigators previously developed a successful PE treatment in symptomatic RI injuries&#xD;
      via the antioxidant pathway, in clinical phase II and III trails and experiments obtaining a&#xD;
      major significant radiation-induced fibrosis regression, then the PE clodronate combination&#xD;
      (PENTOCLO), obtaining a rapid and significant healing of mandible osteoradionecrosis and&#xD;
      significant neurological signs regression (- 35% modified SOMA score at 18 months) in 50&#xD;
      partial RIP.&#xD;
&#xD;
      The aim of this phase III randomized clinical trial is to show PENTOCLO efficiency and its&#xD;
      tolerance in long survival patients irradiated before for cancer and presenting with partial&#xD;
      RIP of upper or lower legs.&#xD;
&#xD;
      The investigators calculated to include 60 patients to show a significant clinical difference&#xD;
      between the two groups after 18 months of treatment: PENTOCLO[Pentoxifylline 400 (2x/d) +&#xD;
      vitamine E 500 (2x/d) + intermittent Clodronate 800 (2/d, 5d/7)] versus triple placebo, with&#xD;
      prednisone 20 (2d/7) for all patients.&#xD;
&#xD;
      RIP is assessed before treatment and every 6 months by a standardized sensory-motor&#xD;
      neurological (SOMA 95 modified by NCI-CTC 99) score used for main criteria at M18, and&#xD;
      various neurological scales of assessment (Visual Analog Scale for pain / VAS for&#xD;
      paresthesia, Neuropathic Pain Symptom Inventory [NPSI], Overall Disability Sum Score [ODSS],&#xD;
      muscle testing, Nine hole peg test / Timed 25-Foot Walk), quality of life (SF36, Patient&#xD;
      Global Impression of Change and Clinical Global impression of Change [PGIC/ CGIC]) and&#xD;
      electrophysiology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this phase III randomized clinical trial is to show PENTOCLO efficiency and its&#xD;
      tolerance in long survival patients irradiated before for cancer and presenting with partial&#xD;
      RIP of upper or lower legs.&#xD;
&#xD;
      We calculated to include 60 patients to show a significant clinical difference between the&#xD;
      two groups after 18 months of treatment: PENTOCLO [Pentoxifylline 400 (2x/d) + vitamine E 500&#xD;
      (2x/d) + intermittent Clodronate 800 (2/d, 5d/7)] versus triple placebo, with prednisone 20&#xD;
      (2d/7) for all patients.&#xD;
&#xD;
      RIP is assessed before treatment and every 6 months by a standardized sensory-motor&#xD;
      neurological (SOMA 95 modified by NCI-CTC 99) score used for main criteria at M18, and&#xD;
      various neurological scales of assessment (Visual Analog Scale [VAS] for pain / VAS for&#xD;
      paresthesia, Neuropathic Pain Symptom Inventory [NPSI], Overall Disability Sum Score [ODSS],&#xD;
      muscle testing, Nine hole peg test / Timed 25-Foot Walk), quality of life (SF36, Patient&#xD;
      Global Impression of Change and Clinical Global impression of Change [PGIC/ CGIC]) and&#xD;
      electrophysiology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensory-motor neurological clinical assessment</measure>
    <time_frame>18 months</time_frame>
    <description>Sensory-motor neurological clinical assessment of RIP patients as measured with SOMA scale (Subjective Objective Medical management Analytic involving tools) modified by NCI-CTC99 scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain VAS</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Visual analog scale for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPSI scale</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>NPSI (Neuropathic Pain Symptom Inventory) pain scale to assess neuropathic pain by a self-questionnaire [Reference: Bouhassira et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004;108(3):248-57]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paresthesia VAS</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Visual analog scale for paresthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequence of paresthesia</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Evaluated on a 4-item scale:&#xD;
Never&#xD;
Occasional (several times each week or month)&#xD;
Intermittent (several times a day)&#xD;
Permanent (all day long and night)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODSS</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Overall disability sum score: Checklist for upper limb (5 items) and lower limb (7 items)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle testing</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Semi-quantitative manual muscle strength assessment on a 0 to 5 scale, separately for each muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological examination</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Evaluation of sensitivity, motricity and reflex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor assessment of complex movements</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Evaluated by two separate tests according to upper vs lower limb involvement:&#xD;
Nine Hole Peg test for brachial injury&#xD;
Timed 25-Foot Walk for lower limb symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Global quality of life as evaluated by SF36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global clinical impression</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Patient global impression of change (PGIC) and clinical global impression of change (CGIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electromyography</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Electromyography of upper / lower limbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms evaluation</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Clinical evaluation looking for upper digestive disorders (nausea, vomiting, epigastralgia), lower digestive disorders (diarrhea), vascular disorders (cephalalgia, vertigo, flush, deep asthenia), bleeding (hematoma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological evaluation</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>evaluation of biological parameters: blood cell count, platelets, sedimentation velocity, C-reactive protein, prothrombin time, TCK, calcemia, protidemia, LDH, creatininemia, phosphokinase creatine (CPK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular evaluation</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>As evaluated by:&#xD;
Heart rate&#xD;
Blood pressure lying and standing after 5 minutes orthostatism&#xD;
Electrocardiogramm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Radiation Induced Brachial Plexopathy</condition>
  <arm_group>
    <arm_group_label>PENTOCLO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Association pentoxifylline, tocopherol and clodronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Triple placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline placebo</intervention_name>
    <description>Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Pentoxifylline 400 mg: 1 cp twice a day (7d/7)</description>
    <arm_group_label>PENTOCLO</arm_group_label>
    <other_name>Pentoxifylline 400 mg: 1 cp twice a day (7d/7)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocopherol acetate</intervention_name>
    <description>Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)</description>
    <arm_group_label>PENTOCLO</arm_group_label>
    <other_name>Tocopherol alpha-acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clodronic Acid</intervention_name>
    <description>Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)</description>
    <arm_group_label>PENTOCLO</arm_group_label>
    <other_name>Clodronate disodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocopherol placebo</intervention_name>
    <description>Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clodronate placebo</intervention_name>
    <description>Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Past-history of post-operative or exclusive irradiation (RT) for currently in&#xD;
             remission cancer, in particular&#xD;
&#xD;
               -  breast cancer with breast or thoracic anterior wall RT; axilla-subclavicular&#xD;
                  lymph nodes RT; sometimes lung or head/neck cancer&#xD;
&#xD;
               -  Lymphoma (Hodgkin or non Hodgkin) with axilla-subclavicular RT (upper limb) or&#xD;
                  lumbar-aortic (lower limbs) or testis tumor&#xD;
&#xD;
          -  Delay RT-RIP more than 6 months, but partial RIP&#xD;
&#xD;
          -  Neurological injury in irradiated volume confirmed by EMG&#xD;
&#xD;
          -  Patient living within distance compatible with day-hospitalization&#xD;
&#xD;
          -  Use of effective contraception for fertile women&#xD;
&#xD;
          -  Signed written informed consent (in case of motor paralysis informed consent is signed&#xD;
             by a witness)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Localized or metastatic cancer recurrence (axillar MRI or PET scan)&#xD;
&#xD;
          -  Complete plexus injury with total motor paralysis of upper/ lower limb for more than 2&#xD;
             years&#xD;
&#xD;
          -  Associated neurological disease that may interferer with the assessment of endpoints&#xD;
&#xD;
          -  Hemorrhage, disease with hemorrhagic risk, unbalanced diabetes&#xD;
&#xD;
          -  Known hypersensitivity to Pentoxifylline, one of the excipients or biphosphonates&#xD;
&#xD;
          -  Renal failure, liver failure or decompensated heart failure&#xD;
&#xD;
          -  Taking another biphosphonate&#xD;
&#xD;
          -  Evolving virosis (hepatitis, herpes, zona) or live vaccine (influenza)&#xD;
&#xD;
          -  Uncontrolled psychotic condition&#xD;
&#xD;
          -  Informed consent not obtained&#xD;
&#xD;
          -  Fertile women who do not want or cannot use effective contraception during the&#xD;
             administration of study drugs&#xD;
&#xD;
          -  Women pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Delanian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncologie-Radiothérapie, Hôpital Saint Louis , Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brachial Plexus Neuropathies</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clodronic Acid</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

